AR and prostate cancer: In summary, we propose that NRIP and DDB2, through competitive binding to the AR, antagonize each other's function in maintaining AR homeostasis and disruption of the balance between these two proteins may contribute to the pathogenesis of a specific type of aggressive prostate cancer.